In 2008, the U.S Food and Drug Administration (FDA) issued a communication warning of the possibility of severe and sometimes incapacitating bone, joint or muscle pain. A study conducted by the American Society of Bone and Mineral Research concluded that long-term use of bisphosphonates, including Boniva, may increase the risk of a rare but serious fracture of the femur. The drug also has been associated with osteonecrosis of the jaw, relatively rare but serious condition.
Ibandronic acid
Medronic acid
Risedronic acid
Alendronic acid
Pamidronic acid
Zoledronic acid
Bolazine capronate
Etidronic acid